EGFR and pancreatic adenocarcinoma: Clinical trials with EGFR inhibitors have failed to demonstrate efficacy, albeit preclinical studies have indicated a clear role of EGFR in pancreatic adenocarcinoma (PDAC)17, 18, 19, and its functional role in non-small lung20, 21 and head and neck cancer22, 23, 24.